Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | YAP1 | P46937 | 3/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064484 | 1.00 | JAK2 (0.48) | JAK2JAK1YAP1GPR119PRMT5 | |
| SCHEMBL3569677 | 0.88 | RIPK2 (0.42) | — | |
| SCHEMBL652089 | 0.86 | GPR119 (0.48) | JAK2JAK1YAP1GPR119PRMT5 | |
| SCHEMBL652088 | 0.86 | GPR119 (0.48) | JAK2JAK1YAP1GPR119PRMT5 | |
| SCHEMBL652471 | 0.82 | GPR119 (0.47) | GPR119 | |
| SCHEMBL6263583 | 0.81 | GPR119 (0.61) | YAP1GPR119 | |
| SCHEMBL4113401 | 0.80 | GPR119 (0.47) | GPR119 | |
| SCHEMBL4113397 | 0.80 | GPR119 (0.47) | GPR119 | |
| SCHEMBL651844 | 0.80 | GPR119 (0.66) | GPR119 | |
| SCHEMBL654092 | 0.80 | GPR119 (0.66) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2700639-A1 | Selective ligands for the neuronal nicotinic receptors and uses thereof | Abbvie Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-8648084-B2 | Selective substituted pyrazine ligands for neuronal nicotinic receptors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120190692-A1 | SELECTIVE SUBSTITUTED PYRIDINE LIGANDS FOR NEURONAL NICOTINIC RECEPTORS | ABBVIE INC. | 2012-07-26 | — | — | US | disclosed |
| US-8148408-B2 | Selective substituted pyridine ligands for neuronal nicotinic receptors | ABBOTT LABORATORIES (US) | 2012-04-03 | — | — | US | disclosed |
| US-8119635-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2298775-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2295437-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20090281118-A1 | Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof | ABBOTT LABORATORIES (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190692-A1 | SELECTIVE SUBSTITUTED PYRIDINE LIGANDS FOR NEURONAL NICOTINIC RECEPTORS | CHRNA4, CHRNB4, CHRNA2 | JAK2 4682/4885JAK1 4486/4885YAP1 3215/4885 |
| US-20090281118-A1 | Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof | CHRNA4, CHRNB4, CHRNA2 | JAK2 4823/4885JAK1 4742/4885YAP1 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.